MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.355
-0.015 (-4.11%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.370
Open0.385
Bid0.000 x 2900
Ask0.000 x 800
Day's Range0.355 - 0.385
52 Week Range0.324 - 1.600
Volume53,584
Avg. Volume395,181
Market Cap33.383M
Beta1.37
PE Ratio (TTM)N/A
EPS (TTM)-0.169
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    –Management intently focused on advancing proprietary and highly differentiated lipid nano-crystal platform delivery technology–. –Multiple discussions with strategic partners remain ongoing–. –­Lead platform-validating ...

  • ACCESSWIRE20 days ago

    Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on NEPT sign up now at www.wallstequities.com/registration. Under evaluation this morning are the following equities: Magenta Therapeutics Inc. (MGTA), Matinas BioPharma Holdings Inc. (NYSE AMER: MTNB), MyoKardia Inc. (NASDAQ: MYOK), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).

  • GlobeNewswirelast month

    NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative medicines using its proprietary lipid nano-crystal (LNC) platform delivery technology, and the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), today announced a research collaboration focused on the development of a novel therapy for the treatment of human immunodeficiency virus (HIV) combining targeted antisense oligonucleotides (ASO) and Matinas’ LNC delivery technology.

  • GlobeNewswire2 months ago

    Matinas BioPharma Announces Closing of $8.0 Million Public Offering

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced that its public offering of 8,000 shares of its newly designated Series B Convertible Preferred Stock, or the Series B Preferred, with a stated value of $1,000 per share and convertible into an aggregate of 16,000,000 shares of its common stock at a conversion price of $0.50 per share, closed on June 21, 2018. Holders of the Series B Preferred will be entitled to receive dividends payable in shares of common stock equal to (i) 10% of the shares of common stock underlying the Series B Preferred then held by such holder on the 12-month anniversary of the offering, (ii) 15% of the shares of common stock underlying the Series B Preferred then held by such holder on the 24-month anniversary of the offering and (iii) 20% of the shares of common stock underlying the Series B Preferred then held by such holder on the 36-month anniversary of the offering.

  • GlobeNewswire2 months ago

    Matinas BioPharma Announces Pricing of $8.0 Million Public Offering

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced the pricing of a public offering of up to 8,000 shares of its newly designated Series B Convertible Preferred Stock, or the Series B Preferred, with a stated value of $1,000 per share and convertible into an aggregate of 16,000,000 shares of its common stock at a conversion price of $0.50 per share. Holders of the Series B Preferred will be entitled to receive dividends payable in shares of common stock equal to (i) 10% of the shares of common stock underlying the Series B Preferred then held by such holder on the 12-month anniversary of the offering, (ii) 15% of the shares of common stock underlying the Series B Preferred then held by such holder on the 24-month anniversary of the offering and (iii) 20% of the shares of common stock underlying the Series B Preferred then held by such holder on the 36-month anniversary of the offering.

  • GlobeNewswire2 months ago

    Matinas BioPharma to Present at the 20th ICHS Symposium on Infections in the Immunocompromised Host

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced that Jerome D. Jabbour, Chief Executive Officer of Matinas, will present at the 20th  International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised Host, being held June 17-19, 2018 in Athens, Greece. The ICHS Symposium is the premier, international, multi-disciplinary forum for scientific and clinical interchange to improve understanding and management of the immunocompromised host and is hosted by Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM, FAAAS.

  • Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near?
    Simply Wall St.2 months ago

    Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near?

    Matinas BioPharma Holdings Inc’s (AMEX:MTNB): Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in theRead More...

  • GlobeNewswire2 months ago

    Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced it will present data in two poster sessions at The American Society for Microbiology’s ASM Microbe 2018 scientific meeting being held June 7–11 in Atlanta, GA. “We continue to explore the broad capabilities of our LNC technology platform as we advance our lead product candidate, MAT2203, towards a potential Phase 2 pivotal trial for prevention of invasive fungal infections (IFIs) in patients with acute lymphoblastic leukemia (ALL).

  • ACCESSWIRE5 months ago

    Matinas BioPharma Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Matinas BioPharma Holdings, Inc. (NYSE American: MTNB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at ...